NOTRELOAD AI
  • NOTRELOAD AI
  • XYZ.
  • XY.
  • #TrumpTrade
  • Discord
  • Buy Me a Coffee →
Sign in Subscribe

This post is for paying subscribers only

Already have an account? Sign in.

Beam Therapeutics' Edge Against Wave's Trial Data

Beam Therapeutics rallied after Wave Life Sciences' WVE-006 trial data for alpha-1 antitrypsin deficiency (AATD) fell below expectations.

09/03/2025 · 1:24 PM
BEAM
/ Read more

Feed↓

Breast Cancer Cells
Featured/ 09/05/2025 · 9:26 AM

BioNTech's Trastuzumab Pamirtecan Achieves Phase 3 Success for HER2-Positive Breast Cancer

BioNTech's new "smart bomb" cancer drug, trastuzumab pamirtecan, excelled in trials for HER2+ breast cancer, beating an older therapy. This marks BioNTech's first major oncology success and offers a promising new option for patients, globally.

/ Subscriber only
09/05/2025 · 8:18 AM

CERo Therapeutics: AML Drug Gains FDA Fast Track

CERo's AML drug, CER-1236, received FDA Fast Track & Orphan Drug status and is in a Phase 1/1b trial. CERo Therapeutics faces a Nasdaq delisting challenge due to low stockholders' equity, but has appealed and plans to raise funds.

/ Subscriber only
09/05/2025 · 7:58 AM

CG Oncology's Cretostimogene: Durable Response in High-Risk Bladder Cancer

Cretostimogene, a new bladder cancer treatment, shows durable 24-month complete responses (41.8%) in high-risk patients unresponsive to BCG. It has a good safety profile and offers bladder-sparing potential, with approval submission planned.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Buy Me a Coffee
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe